CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2022 RESULTS FROM CONTINUING OPERATIONS
Core Laboratories N.V. (NYSE: CLB) reported fourth-quarter 2022 revenue of $128 million, a slight sequential increase, with operating income of $16 million and GAAP EPS of $0.14. Adjusted EPS was $0.20, reflecting a 10% sequential rise. Despite challenges from currency fluctuations and the Russia-Ukraine conflict, free cash flow reached $11.2 million, and net debt fell by $11.7 million. The firm announced its voluntary delisting from Euronext and redomestication to the U.S. for improved efficiencies. Looking ahead, Core anticipates 2023 revenue between $125-$129 million, with a slight decline in Reservoir Description segment revenue due to seasonal patterns.
- Sequential revenue increased to $128 million.
- Fourth-quarter operating income rose to $16 million.
- Free cash flow reached $11.2 million.
- Net debt reduced by $11.7 million sequentially.
- 2022 revenue impacted by approximately $22.8 million due to currency and geopolitical issues.
- Reservoir Description revenue down slightly due to geopolitical sanctions.
- Continuous volatility in crude-oil trading patterns poses risks.
- FOURTH QUARTER REVENUE OF
; UP SLIGHTLY SEQUENTIALLY$128 MILLION - FOURTH QUARTER OPERATING INCOME OF
; EX-ITEMS OF$16 MILLION , UP$15 MILLION 10% SEQUENTIALLY - FOURTH QUARTER OPERATING MARGIN, EX-ITEMS, OF
12% WITH SEQUENTIAL INCREMENTAL MARGINS EXCEEDING80% , DRIVEN BY PRODUCTION ENHANCEMENT - FOURTH QUARTER GAAP EPS OF
; EX-ITEMS,$0.14 $0.20 - FOURTH QUARTER CASH FROM OPERATIONS OF
$13.2 MILLION - FOURTH QUARTER FREE CASH FLOW OF
$11.2 MILLION - FOURTH QUARTER NET DEBT REDUCED BY
SEQUENTIALLY$11.7 MILLION - COMPANY ANNOUNCED DELISTING FROM EURONEXT AND REDOMESTICATION TO THE
U.S. - COMPANY ANNOUNCES Q1 2023 QUARTERLY DIVIDEND
For 2022, Core's revenue of
Core's CEO,
Voluntary Delisting from Euronext and Redomestication to
On
Following the delisting of the shares, on
Benefits of the Redomestication include: (i) a reduction in the corporate footprint and regulatory requirements associated with preparing duplicative audited financial statements and other reporting obligations, (ii) improved efficiencies and opportunities in the Company's corporate treasury, cash management, risk management and tax functions, and (iii) a simplified and more efficient tax structure.
Reservoir Description
Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately
Reservoir Description revenue for 2022 was adversely impacted by the devaluation of the Euro and British Pound when translated into
During the fourth quarter of 2022, under the direction of a
Also, during the fourth quarter of 2022, Core received both reservoir fluid and reservoir rock samples from Talos Energy Inc.'s Deepwater Gulf of Mexico Lime Rock and
Production Enhancement
Production Enhancement operations, which are focused on complex completions in unconventional, tight-oil reservoirs in the
During the fourth quarter of 2022, a
Liquidity, Free Cash Flow and Dividend
Core continues to focus on maximizing FCF, a non-GAAP financial measure defined as cash from operations less capital expenditures. For the fourth quarter of 2022, cash from operations was
During the fourth quarter of 2022, Core's net debt was reduced by
On
On
The Board and the Company's Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and FCF, factors that have high correlation to total shareholder return. Core's commitment to an asset-light business model and disciplined capital stewardship promotes capital efficiency and is designed to produce more predictable and superior long-term ROIC.
The Board has established an internal performance metric of demonstrating superior ROIC performance relative to the oilfield service companies listed as Core's
Industry and Core Lab Outlook and Guidance
Looking forward into 2023, Core sees crude-oil macro fundamentals continuing to support a multi-year recovery cycle for the oil and gas industry. Crude-oil demand for 2023, as forecast by the
Turning to the
As customary, Core expects typical sequential seasonal industry patterns will cause activity in the first quarter of 2023 to decline in some regions. As such, Core anticipates Reservoir Description first quarter 2023 revenue to be down low to mid-single digits, sequentially. Continued volatility with crude-oil trading patterns may impact Core's Reservoir Description segment's international growth within its Russian, Ukrainian and European operations. Production Enhancement segment revenue is estimated to be up mid-single digits as
Core projects first quarter 2023 revenue to range from
The Company's first quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. First quarter 2023 guidance also assumes an effective tax rate of
Earnings Call Scheduled
The Company has scheduled a conference call to discuss Core's fourth quarter 2022 earnings announcement. The call will begin at
The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.
Visit the Company's website at www.corelab.com. Connect with
CORE LABORATORIES N.V. & SUBSIDIARIES | |||||||||||||||||
Quarter Ended | % Variance | ||||||||||||||||
vs. Q3-2022 | vs. Q4-2021 | ||||||||||||||||
REVENUE | $ | 127,571 | $ | 125,966 | $ | 125,139 | 1.3 % | 1.9 % | |||||||||
OPERATING EXPENSES: | |||||||||||||||||
Costs of services and product sales | 99,816 | 98,930 | 96,987 | 0.9 % | 2.9 % | ||||||||||||
General and administrative expense | 8,724 | 10,001 | 10,927 | (12.8) % | (20.2) % | ||||||||||||
Depreciation and amortization | 4,073 | 4,171 | 4,398 | (2.3) % | (7.4) % | ||||||||||||
Other (income) expense, net | (660) | (1,781) | (1,373) | NM | NM | ||||||||||||
Total operating expenses | 111,953 | 111,321 | 110,939 | 0.6 % | 0.9 % | ||||||||||||
OPERATING INCOME (LOSS) | 15,618 | 14,645 | 14,200 | 6.6 % | 10.0 % | ||||||||||||
Interest expense | 3,081 | 3,138 | 2,590 | (1.8) % | 19.0 % | ||||||||||||
Income (loss) from continuing operations | 12,537 | 11,507 | 11,610 | 9.0 % | 8.0 % | ||||||||||||
Income tax expense (benefit) | 5,847 | 3,856 | 8,823 | 51.6 % | (33.7) % | ||||||||||||
Income (loss) from continuing operations | 6,690 | 7,651 | 2,787 | (12.6) % | 140.0 % | ||||||||||||
Net income (loss) | 6,690 | 7,651 | 2,787 | (12.6) % | 140.0 % | ||||||||||||
Net income (loss) attributable to non- | (61) | 127 | 99 | NM | NM | ||||||||||||
Net income (loss) attributable to Core | $ | 6,751 | $ | 7,524 | $ | 2,688 | (10.3) % | 151.2 % | |||||||||
Diluted earnings (loss) per share from | $ | 0.14 | $ | 0.16 | $ | 0.06 | (12.5) % | 133.3 % | |||||||||
Diluted earnings (loss) per share | $ | 0.14 | $ | 0.16 | $ | 0.06 | (12.5) % | 133.3 % | |||||||||
Diluted weighted average common shares | 46,826 | 47,012 | 46,927 | (0.4) % | (0.2) % | ||||||||||||
Effective tax rate | 47 | % | 34 | % | 76 | % | NM | NM | |||||||||
SEGMENT INFORMATION: | |||||||||||||||||
Revenue: | |||||||||||||||||
Reservoir Description | $ | 78,124 | $ | 78,996 | $ | 80,097 | (1.1) % | (2.5) % | |||||||||
Production Enhancement | 49,447 | 46,970 | 45,042 | 5.3 % | 9.8 % | ||||||||||||
Total | $ | 127,571 | $ | 125,966 | $ | 125,139 | 1.3 % | 1.9 % | |||||||||
Operating income (loss): | |||||||||||||||||
Reservoir Description | $ | 6,817 | $ | 9,798 | $ | 7,216 | (30.4) % | (5.5) % | |||||||||
Production Enhancement | 7,904 | 4,417 | 6,993 | 78.9 % | 13.0 % | ||||||||||||
Corporate and Other | 897 | 430 | (9) | NM | NM | ||||||||||||
Total | $ | 15,618 | $ | 14,645 | $ | 14,200 | 6.6 % | 10.0 % | |||||||||
"NM" means not meaningful | |||||||||||||||||
CORE LABORATORIES N.V. & SUBSIDIARIES | |||||||||||
Year Ended | % Variance | ||||||||||
2022 | 2021 | ||||||||||
REVENUE | $ | 489,735 | $ | 470,252 | 4.1 % | ||||||
OPERATING EXPENSES: | |||||||||||
Costs of services and product sales | 393,655 | 367,896 | 7.0 % | ||||||||
General and administrative expense | 38,117 | 44,173 | (13.7) % | ||||||||
Depreciation and amortization | 17,161 | 18,516 | (7.3) % | ||||||||
Other (income) expense, net | (722) | (5,595) | NM | ||||||||
Total operating expenses | 448,211 | 424,990 | 5.5 % | ||||||||
OPERATING INCOME (LOSS) | 41,524 | 45,262 | (8.3) % | ||||||||
Interest expense | 11,570 | 9,152 | 26.4 % | ||||||||
Income (loss) from continuing operations before income taxes | 29,954 | 36,110 | (17.0) % | ||||||||
Income tax expense (benefit) | 10,296 | 15,891 | (35.2) % | ||||||||
Income (loss) from continuing operations | 19,658 | 20,219 | (2.8) % | ||||||||
Net income (loss) | 19,658 | 20,219 | (2.8) % | ||||||||
Net income (loss) attributable to non-controlling interest | 205 | 492 | NM | ||||||||
Net income (loss) attributable to | $ | 19,453 | $ | 19,727 | (1.4) % | ||||||
Diluted earnings (loss) per share from continuing operations | $ | 0.42 | $ | 0.43 | (2.3) % | ||||||
Diluted earnings (loss) per share attributable to | $ | 0.42 | $ | 0.42 | — % | ||||||
Diluted weighted average common shares outstanding | 46,813 | 46,690 | 0.3 % | ||||||||
Effective tax rate | 34 | % | 44 | % | NM | ||||||
SEGMENT INFORMATION: | |||||||||||
Revenue: | |||||||||||
Reservoir Description | $ | 307,691 | $ | 313,609 | (1.9) % | ||||||
Production Enhancement | 182,044 | 156,643 | 16.2 % | ||||||||
Total | $ | 489,735 | $ | 470,252 | 4.1 % | ||||||
Operating income (loss): | |||||||||||
Reservoir Description | $ | 22,902 | $ | 28,958 | (20.9) % | ||||||
Production Enhancement | 16,351 | 15,163 | 7.8 % | ||||||||
Corporate and Other | 2,271 | 1,141 | 99.0 % | ||||||||
Total | $ | 41,524 | $ | 45,262 | (8.3) % | ||||||
"NM" means not meaningful |
CORE LABORATORIES N.V. & SUBSIDIARIES | |||||||||||||||||
% Variance | |||||||||||||||||
ASSETS: | vs. Q3-2022 | vs. Q4-2021 | |||||||||||||||
Cash and cash equivalents | $ | 15,428 | $ | 13,732 | $ | 17,703 | 12.4 % | (12.9) % | |||||||||
Accounts receivable, net | 106,913 | 100,195 | 96,830 | 6.7 % | 10.4 % | ||||||||||||
Inventories | 60,445 | 54,795 | 45,443 | 10.3 % | 33.0 % | ||||||||||||
Other current assets | 28,916 | 26,493 | 29,079 | 9.1 % | (0.6) % | ||||||||||||
Total current assets | 211,702 | 195,215 | 189,055 | 8.4 % | 12.0 % | ||||||||||||
Property, plant and equipment, net | 105,028 | 107,252 | 110,952 | (2.1) % | (5.3) % | ||||||||||||
Right of use assets | 52,379 | 56,589 | 61,387 | (7.4) % | (14.7) % | ||||||||||||
Intangibles, goodwill and other long-term assets, net | 209,245 | 211,134 | 219,459 | (0.9) % | (4.7) % | ||||||||||||
Total assets | $ | 578,354 | $ | 570,190 | $ | 580,853 | 1.4 % | (0.4) % | |||||||||
LIABILITIES AND EQUITY: | |||||||||||||||||
Accounts payable | $ | 45,847 | $ | 34,343 | $ | 29,726 | 33.5 % | 54.2 % | |||||||||
Operating lease liabilities | 11,699 | 11,472 | 12,342 | 2.0 % | (5.2) % | ||||||||||||
Other current liabilities | 45,589 | 41,544 | 48,714 | 9.7 % | (6.4) % | ||||||||||||
Total current liabilities | 103,135 | 87,359 | 90,782 | 18.1 % | 13.6 % | ||||||||||||
Long-term debt, net | 172,386 | 182,677 | 188,636 | (5.6) % | (8.6) % | ||||||||||||
Long-term operating lease liabilities | 38,305 | 41,975 | 49,286 | (8.7) % | (22.3) % | ||||||||||||
Other long-term liabilities | 75,574 | 74,886 | 91,148 | 0.9 % | (17.1) % | ||||||||||||
Total equity | 188,954 | 183,293 | 161,001 | 3.1 % | 17.4 % | ||||||||||||
Total liabilities and equity | $ | 578,354 | $ | 570,190 | $ | 580,853 | 1.4 % | (0.4) % |
CORE LABORATORIES N.V. & SUBSIDIARIES | ||||||||
Year Ended | ||||||||
2022 | 2021 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Income (loss) from continuing operations | $ | 19,658 | $ | 20,219 | ||||
Income (loss) from discontinued operations, net of income taxes | — | — | ||||||
Net income (loss) | 19,658 | 20,219 | ||||||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
Stock-based compensation | 7,756 | 19,093 | ||||||
Depreciation and amortization | 17,161 | 18,516 | ||||||
Deferred income taxes | 433 | 6,012 | ||||||
Gain on sale of business | — | (1,012) | ||||||
Accounts receivable | (10,078) | (13,522) | ||||||
Inventories | (14,860) | (4,547) | ||||||
Accounts payable | 15,374 | 6,568 | ||||||
Other adjustments to net income (loss) | (10,488) | (14,748) | ||||||
Net cash provided by operating activities | 24,956 | 36,579 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Capital expenditures | (10,216) | (13,539) | ||||||
Proceeds from insurance recovery | 583 | 726 | ||||||
Other investing activities | 5,777 | 2,590 | ||||||
Net cash used in investing activities | (3,856) | (10,223) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Repayment of long-term debt | (131,000) | (226,000) | ||||||
Proceeds from long-term debt | 116,000 | 155,000 | ||||||
Proceeds from issuance of common shares | — | 60,000 | ||||||
Transaction costs on equity distribution program | (411) | (861) | ||||||
Dividends paid | (1,853) | (1,834) | ||||||
Repurchase of common shares | (3,903) | (8,256) | ||||||
Other financing activities | (2,208) | (508) | ||||||
Net cash used in financing activities | (23,375) | (22,459) | ||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | (2,275) | 3,897 | ||||||
CASH AND CASH EQUIVALENTS, beginning of year | 17,703 | 13,806 | ||||||
CASH AND CASH EQUIVALENTS, end of year | $ | 15,428 | $ | 17,703 |
Non-GAAP Information
Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, management uses certain non-GAAP measures that exclude these Items and believes that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statements and filings with the
Reconciliation of Operating Income (Loss), Income (Loss) from Continuing Operations and | ||||||||||||||||||||
Operating Income (Loss) | ||||||||||||||||||||
Quarter Ended | ||||||||||||||||||||
GAAP reported | $ | 15,618 | $ | 14,645 | $ | 14,200 | ||||||||||||||
Stock compensation (1) | (1,868) | — | — | |||||||||||||||||
Redomestication costs | 246 | — | — | |||||||||||||||||
Foreign exchange losses (gains) | 691 | (1,303) | (32) | |||||||||||||||||
Excluding specific items | $ | 14,687 | $ | 13,342 | $ | 14,168 | ||||||||||||||
Income (Loss) from Continuing Operations | ||||||||||||||||||||
Quarter Ended | ||||||||||||||||||||
GAAP reported | $ | 6,690 | $ | 7,651 | $ | 2,787 | ||||||||||||||
Stock compensation (1) | (1,494) | — | — | |||||||||||||||||
Redomestication costs | 197 | — | — | |||||||||||||||||
Foreign exchange losses (gains) | 552 | (1,043) | (26) | |||||||||||||||||
Debt issuance costs write off (3) | — | 171 | — | |||||||||||||||||
Impact of higher (lower) tax rate (4) | 3,341 | 1,553 | 6,501 | |||||||||||||||||
Excluding specific items | $ | 9,286 | $ | 8,332 | $ | 9,262 | ||||||||||||||
Diluted Earnings (Loss) Per Share from Continuing Operations | ||||||||||||||||||||
Quarter Ended | Year ended | |||||||||||||||||||
GAAP reported | $ | 0.14 | $ | 0.16 | $ | 0.06 | $ | 0.42 | ||||||||||||
Stock compensation (1), (2) | (0.03) | — | — | (0.01) | ||||||||||||||||
Severance and other charges | — | — | — | 0.06 | ||||||||||||||||
Bad debt | — | — | — | 0.01 | ||||||||||||||||
Foreign exchange losses (gains) | 0.02 | (0.01) | — | 0.01 | ||||||||||||||||
Impact of higher (lower) tax rate (4) | 0.07 | 0.03 | 0.14 | 0.08 | ||||||||||||||||
Excluding specific items | $ | 0.20 | $ | 0.18 | $ | 0.20 | $ | 0.57 | ||||||||||||
(1) Quarter ended | ||||||||||||||||||||
(2) The year ended | ||||||||||||||||||||
(3) Quarter ended | ||||||||||||||||||||
(4) Includes adjustments to reflect tax expense at a normalized rate of |
Segment Information | ||||||||||||
Operating Income (Loss) from Continuing Operations | ||||||||||||
Quarter Ended | ||||||||||||
Reservoir Description | Production Enhancement | Corporate and Other | ||||||||||
GAAP reported | $ | 6,817 | $ | 7,904 | $ | 897 | ||||||
Stock compensation (1) | (1,250) | (618) | — | |||||||||
Redomestication costs | 156 | 90 | — | |||||||||
Foreign exchange losses (gains) | 321 | 309 | 61 | |||||||||
Excluding specific items | $ | 6,044 | $ | 7,685 | $ | 958 | ||||||
(1) Quarter ended |
Return on
Return on
ROIC of
Free Cash Flow
Core uses the non-GAAP measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is an important measurement because it represents the cash from operations, in excess of capital expenditures, available to operate the business and fund non-discretionary obligations. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative consideration to operating income, net income, earnings per share, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash flow should not be considered a measure of liquidity. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.
Computation of Free Cash Flow | ||||||||
Quarter Ended | Year Ended | |||||||
Net cash provided by operating activities | $ | 13,211 | $ | 24,956 | ||||
Capital expenditures | (2,021) | (10,216) | ||||||
Free cash flow | $ | 11,190 | $ | 14,740 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/core-lab-reports-fourth-quarter-and-full-year-2022-results-from-continuing-operations-301736654.html
SOURCE
FAQ
What were Core Laboratories' Q4 2022 earnings results?
How much did Core Laboratories reduce its net debt in Q4 2022?
What is Core Laboratories' guidance for Q1 2023 revenue?
Why did Core Laboratories announce delisting from Euronext?